
-
SpringWorks Therapeutics Inc NasdaqGS:SWTX SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial. In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Location: 100 Washington Boulevard, Stamford, CT, 06902, United States | Website: https://www.springworkstx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.236B
Cash
287.9M
Avg Qtr Burn
-41.36M
Short % of Float
8.03%
Insider Ownership
1.28%
Institutional Own.
87.64%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OGSIVEO (Nirogacestat) (gamma secretase inhibitor) Details Desmoid tumors | Approved Quarterly sales | |
GOMEKLI™ (mirdametinib) Details NF1-associated Plexiform Neurofibromas, Cancer | Approved Quarterly sales | |
Nirogacestat Details Cancer, Ovarian cancer, recurrent ovarian granulosa cell tumors | Phase 2 Data readout | |
Mirdametinib + lifirafenib Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
Brimarafenib (BGB-3245) + mirdametinib Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
Nirogacestat combo w/ belantamab Details Multiple myeloma, Cancer | Phase 1/2 Data readout | |
Mirdametinib (MEK inhibitor) (PD-0325901) Details Cancer, Glioma | Phase 1/2 Data readout | |
Mirdametinib + fulvestrant (Faslodex) Details Breast cancer, Cancer | Phase 1/2 Update | |
Nirogacestat + teclistamab Details Multiple myeloma, Cancer | Phase 1b Data readout | |
Nirogacestat + linvoseltamab Details Cancer, Multiple myeloma | Phase 1b Data readout | |
Brimarafenib (BGB-3245) + panitumumab Details Cancer, Colorectal cancer , Pancreatic cancer | Phase 1b Data readout | |
Brimarafenib (BGB-3245) Details Solid tumor/s, Cancer | Phase 1b Data readout | |
SW-682 [pan-TEAD inhibitor] Details Cancer, Solid tumor/s | Phase 1a Data readout | |
SW-3431 Details Cancer | IND Submission |